Weekly topic: 5 Wealth points for those who answer correctly, 2 Wealth points for participation； Question 160
Thread Content
This post was last edited by ljtjbx on 2015-8-28 09:28. Short answer: What are the basic properties that pharmaceutical polymers should possess? ? Tip: Polymer-based drugs have advantages such as low toxicity, high efficacy, sustained release, and long duration of action. They have good compatibility with blood and tissues, and remain in the body for a long time. The release rate of the drug can also be adjusted by selecting appropriate monomers and varying the copolymer components, thereby enhancing the drug’s efficacy while reducing its toxicity and side effects. Once inside the body, it can effectively reach the affected area. Therefore, the dosage of the medication can be reduced, frequent administration can be avoided, a constant concentration of the drug in the body can be maintained, allowing the pharmacological activity of the drug to persist and enhancing its efficacy. The emergence of synthetic polymer-based drugs has not only addressed the shortcomings of certain traditional drugs but also **expanded the variety of drugs available, providing new means to combat diseases that pose a serious threat to human health.** 1) The polymer drugs themselves, as well as their decomposition products, should be non-toxic, not cause inflammatory or tissue-altering reactions, and have no carcinogenic potential. 2) Drugs that enter the blood system do not cause thrombi. 3) A group that is water-soluble or hydrophilic, and possesses pharmacological activity upon hydrolysis in living organisms. 4) It can effectively reach the lesion site and accumulate there. Maintain a certain concentration. 5) For oral medications, the polymer backbone should not hydrolyze, so that the polymer residues can be excreted from the body through the excretory system. If the drug is introduced into the circulatory system, to prevent its accumulation in the body, the polymer backbone must be easily decomposable so that it can be excreted from the body or absorbed by it.
(1) The polymer drugs themselves, as well as their decomposition products, should be non-toxic, not cause inflammatory or tissue-altering reactions, and possess no carcinogenicity. (2) Drugs that enter the blood system do not cause thrombi. (3) A group that is water-soluble or hydrophilic, and possesses pharmacological activity upon hydrolysis in living organisms. (4) It can effectively reach the lesion site and accumulate there. Maintain a certain concentration. (5) For oral medications, the polymer backbone should not hydrolyze, so that the polymer residues can be excreted from the body through the excretory system. If the drug is introduced into the circulatory system, to prevent its accumulation in the body, the polymer backbone must be easily decomposable so that it can be excreted from the body or absorbed by it.
Polymer-based drugs possess characteristics such as low toxicity, high efficacy, sustained release, and long duration of action.
Basic properties that pharmaceutical polymers should possess: (1) Both the polymer-based drugs themselves and their decomposition products must be non-toxic, must not cause inflammatory or tissue-altering reactions, and must not have carcinogenic properties. (2) Drugs that enter the blood system do not cause thrombi. (3) A group that is water-soluble or hydrophilic, and possesses pharmacological activity upon hydrolysis in living organisms. (4) It can effectively reach the lesion site and accumulate there. Maintain a certain concentration. (5) For oral medications, the polymer backbone should not hydrolyze, so that the polymer residues can be excreted from the body through the excretory system. If the drug is introduced into the circulatory system, to prevent its accumulation in the body, the polymer backbone must be readily decomposable so that it can be excreted from the body or absorbed by it.
The basic properties of pharmaceutical polymers include: (1) Both the polymer-based drugs themselves and their decomposition products should be non-toxic, should not cause inflammatory or tissue-altering reactions, and should not have carcinogenic properties. (2) Drugs that enter the blood system do not cause thrombi. (3) A group that is water-soluble or hydrophilic, and possesses pharmacological activity upon hydrolysis in living organisms. (4) It can effectively reach the lesion site and accumulate there. Maintain a certain concentration. (5) For oral medications, the polymer backbone should not hydrolyze, so that the polymer residues can be excreted from the body through the excretory system. If the drug is introduced into the circulatory system, to prevent its accumulation in the body, the polymer backbone must be easily decomposable so that it can be excreted from the body or absorbed by it.
Basic properties that pharmaceutical polymers should possess: (1) Both the polymer-based drugs themselves and their decomposition products must be non-toxic, not cause inflammatory or tissue-altering reactions, and lack carcinogenicity. (2) Drugs that enter the blood system do not cause thrombi. (3) A group that is water-soluble or hydrophilic, and possesses pharmacological activity upon hydrolysis in living organisms. (4) It can effectively reach the lesion site and accumulate there. Maintain a certain concentration. (5) For oral medications, the polymer backbone should not hydrolyze, so that the polymer residues can be excreted from the body through the excretory system. If the drug is introduced into the circulatory system, to prevent its accumulation in the body, the polymer backbone must be easily decomposable so that it can be excreted from the body or absorbed by it.
1. Anticoagulant and anti-tissue hyperplasia properties of the material surface. 2. Wear resistance of the material. 3. Material immunogenicity and virus elimination (mainly animal-derived medical materials) 4. Material resistance to calcification. 5. Degradable and absorbable properties of the material. 6. Adsorption capacity of the material surface/interface for proteins in vivo. 7. Tissue inducibility of materials (a currently cutting-edge field). 8. Nanoproperties of materials (also a relatively cutting-edge area).
1) The polymer drugs themselves, as well as their decomposition products, should be non-toxic, not cause inflammatory or tissue-altering reactions, and have no carcinogenic potential. 2) Drugs that enter the blood system do not cause thrombi. 3) A group that is water-soluble or hydrophilic, and possesses pharmacological activity upon hydrolysis in living organisms. 4) It can effectively reach the lesion site and accumulate there. Maintain a certain concentration. 5) For oral medications, the polymer backbone should not hydrolyze, so that the polymer residues can be excreted from the body through the excretory system. If the drug is introduced into the circulatory system, to prevent its accumulation in the body, the polymer backbone must be easily decomposable so that it can be excreted from the body or absorbed by it.
1) The polymer drugs themselves, as well as their decomposition products, should be non-toxic, not cause inflammatory or tissue-altering reactions, and have no carcinogenic potential. 2) Drugs that enter the blood system do not cause thrombi. 3) A group that is water-soluble or hydrophilic, and possesses pharmacological activity upon hydrolysis in living organisms. 4) It can effectively reach the lesion site and accumulate there. Maintain a certain concentration. 5) For oral medications, the polymer backbone should not hydrolyze, so that the polymer residues can be excreted from the body through the excretory system. If the drug is introduced into the circulatory system, to prevent its accumulation in the body, the polymer backbone must be easily decomposable so that it can be excreted from the body or absorbed by it.
(1) The polymer drugs themselves, as well as their decomposition products, should be non-toxic, not cause inflammatory or tissue-altering reactions, and possess no carcinogenicity. (2) Drugs that enter the blood system do not cause thrombi. (3) A group that is water-soluble or hydrophilic, and possesses pharmacological activity upon hydrolysis in living organisms. (4) It can effectively reach the lesion site and accumulate there. Maintain a certain concentration. (5) For oral medications, the polymer backbone should not hydrolyze, so that the polymer residues can be excreted from the body through the excretory system. If the drug is introduced into the circulatory system, to prevent its accumulation in the body, the polymer backbone must be easily decomposable so that it can be excreted from the body or absorbed by it.
The most crucial aspect is biocompatibility. Secondly, depending on the type of material and its specific application, the following properties also apply: 1. The material’s surface resistance to blood clotting and tissue proliferation. 2. Wear resistance of the material. 3. Material immunogenicity and virus elimination (mainly animal-derived medical materials) 4. Material resistance to calcification. 5. Degradable and absorbable properties of the material. 6. Adsorption capacity of the material surface/interface for proteins in vivo. 7. Tissue inducibility of materials (a currently cutting-edge field). 8. Nanoproperties of materials (also a relatively cutting-edge area).